1.
Improving Marginal Likelihood Estimation for Bayesian Phylogenetic Model Selection
by Xie, Wangang
Systematic biology, 2011-03-01, Vol.60 (2), p.150-160
2.
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
by Kumada, Hiromitsu
Journal of gastroenterology, 2017-10-20, Vol.53 (4), p.566-575
3.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
by Chayama, Kazuaki
Journal of gastroenterology, 2017-09-25, Vol.53 (4), p.557-565
4.
Posterior Predictive Bayesian Phylogenetic Model Selection
by Lewis, Paul O
Systematic biology, 2014-05-01, Vol.63 (3), p.309-321
5.
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
by Kumada, Hiromitsu
Journal of gastroenterology, 2017-11-13, Vol.53 (5), p.689-689
6.
Covariate-Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences
by Ge, Miaomiao
Drug information journal, 2011-07-01, Vol.45 (4), p.481-493
